176 related articles for article (PubMed ID: 11336593)
1. Current treatment practice for essential thrombocythaemia in adults.
Griesshammer M; Bangerter M; Grünewald M
Expert Opin Pharmacother; 2001 Mar; 2(3):385-93. PubMed ID: 11336593
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of essential thrombocythaemia: economic considerations.
Griesshammer M; Langer C
Expert Opin Pharmacother; 2003 Sep; 4(9):1499-505. PubMed ID: 12943479
[TBL] [Abstract][Full Text] [Related]
3. Essential thrombocythaemia in children: is a treatment needed?
Randi ML; Putti MC
Expert Opin Pharmacother; 2004 May; 5(5):1009-14. PubMed ID: 15155103
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
5. Practical approach to treating essential thrombocythaemia: case studies.
Reilly JT
Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
[No Abstract] [Full Text] [Related]
6. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
7. Update on diagnosis and management of essential thrombocythemia.
Gisslinger H
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):430-6. PubMed ID: 16810619
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G
Ann Hematol; 2009 Jan; 88(1):1-10. PubMed ID: 18629498
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with essential thrombocythemia: current concepts and perspectives.
Briere J; Guilmin F
Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
[TBL] [Abstract][Full Text] [Related]
10. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
11. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
13. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
14. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
15. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Sever M; Newberry KJ; Verstovsek S
Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]